Vaginal progesterone in risk reduction of preterm birth in women with short cervix in the midtrimester of pregnancy

Meena Khandelwal
Department of Obstetrics and Gynecology, Cooper University Hospital, Camden, NJ, USA

Abstract: Preterm birth is a major health problem for the neonate, family, country, and society in general. Despite many risk factors being identified for women destined to deliver preterm, short cervical length detected on transvaginal ultrasound is the most plausible, practical and sensitive risk factor for prediction of spontaneous preterm birth. The definition of short cervix has varied in various studies, but most commonly accepted is ≤2.5 cm in the midtrimester of pregnancy, though risk of spontaneous preterm birth (sPTB) increases as the cervical length decreases. Vaginal progesterone, a naturally occurring steroid hormone, is the most bioavailable form of progesterone for uterine and cervical effects with the fewest side effects. Multiple prospective studies have consistently shown its benefits in decreasing sPTB rate in women with asymptomatic midtrimester short cervix. The safety for mother and fetus, and tolerability of vaginal progesterone, particularly the gel form, is also well established. Vaginal progesterone is a minimally invasive intervention that is not painful and is very safe, with reasonable cost where the benefits (even if argued to be small) clearly outweigh the risks. Thus there should be little hesitation for implementation of universal transvaginal cervical length screening and preventive vaginal progesterone treatment for women with short cervix.

Keywords: preterm birth, progesterone, short cervix

Overview

The incidence of preterm birth in United States in 2010 was 11.99% with 3.5% born < 34 weeks' gestation. This seemingly small group of neonates account for more than 75% of all neonatal deaths and 35.4% of all infant deaths. Of the premature survivors, a quarter have substantial neurological morbidity persisting into adulthood with associated increased emotional, physical, and monetary costs to families and society. The advancements in technology and health care have resulted in improved survival of preterm infants with resultant increase in absolute numbers of cerebral palsy cases and adolescents with cognitive deficits, academic underachieving, grade failures, and increased need for remedial assistance, as well as increase in mental disorders with associated societal consequences. Two-thirds of preterm births in the United States are spontaneous (sPTB) and account for half of infant hospitalization costs and a quarter of pediatric costs. In 2005, over $26.2 billion was spent in the United States on prematurity-related medical problems. It would make sense that decrease in incidence of prematurity would benefit the mother, the child, the family, and society in general with decreased morbidity, mortality, and societal long-term burden as well as cost savings. As an example, CIGNA HealthCare reported a $6000 per pregnancy cost savings with good maternity care resulting in slight decrease in prematurity.
Short cervical length

The first step in prevention of preterm births is adequate identification of at-risk cases (Table 1). For tertiary prevention, onset of uterine contractions with cervical change or rupture of membranes makes it easy to identify patients in preterm labor. Tertiary prevention has proven to be more useful in improving neonatal morbidity with administration of corticosteroids and antibiotics, without much success in actually decreasing the number of preterm births. Therefore, focus has shifted towards primary and secondary prevention and led us to identify multiple risk factors for preterm births (Table 2). However, the sensitivity as well as the positive predictive value of any one of these factors or even a combination is poor. Two of the most important predictors of preterm delivery are prior obstetrical history and cervical effacement measured as shortened cervical length (sCL) by ultrasound. Logistic regression analysis has revealed cervical length (CL) to be the single independent contributor to early sPTB (≤32 weeks) when neonatal morbidity and mortality is highest. This also is the most plausible tool for risk assessment since cervical ripening is also the final detectable pathway prior to onset of term labor. Short cervix has been shown in many prospective trials across different populations (US, British, Finnish) to predict sPTB.

Short cervix can be diagnosed by manual digital exam, by Cervilenz (CerviLenz, Chagrin Falls, OH), transabdominal (TAS) or transvaginal ultrasound (TVS). Manual digital exam is subjective, with high failure rate (inability to assess CL) particularly in asymptomatic women with closed cervix, and differences amongst examiners making standardization of findings difficult. Cervilenz measures the cervico-portion length and in a single prospective trial of 189 patients, correlated with TVS for diagnosing CL < 3 cm with a sensitivity of 88% and specificity of 92%. Its role so far appears to be in weeding out women with normal CL, requires TVS for confirming a sCL, and requires further investigation to establish role in clinical practice. Ultrasound allows objective evaluation of CL, but TVS is favored over TAS. TAS findings result in greater scatter, higher failure rates (6.7% compared to <1% with TVS), and longer cervix estimation from full maternal bladder and resultant higher false-negative rates. TVS is an easy skill to learn for sonographers with reported inter- and intraobserver variability of <5% (or 2–4 mm). TVS is highly reproducible, safe, and minimally invasive with good acceptability by women. CL screening by TVS meets the six criteria of a ‘good screening tool’: validity, reliability, yield, cost, acceptance, and follow-up services. Despite the low sensitivity, the high negative predictive value (>97%) across all trials, makes CL by TVS a useful screening tool for low-risk pregnant women. A sCL is a good screening predictor as it heralds onset of preterm delivery weeks prior, to allow for intervention to prevent it. In addition, sCL can be diagnosed reliably and easily by ultrasound which can be performed at the time of an already scheduled visit for fetal anatomic survey. The infrastructure and equipment for TVS already exist in most centers performing fetal ultrasounds though may not be in certain geographic areas.

Many have advocated universal TVS CL screening in all singleton pregnancies. However, the USA Society of Maternal–Fetal Medicine (SMFM) clinical guideline states, “CL screening in singleton gestations without prior sPTB cannot yet be mandated universally,” despite acknowledging it fulfills criteria for an effective screening test. Yet, the guideline recommends TVS CL measurements every 2 weeks in singletons with prior sPTB and provides management decisions for those who choose universal screening in all singleton gestations. This suggests SMFM is encouraging universal screening without mandating it. Resources for TVS when needed for a certain population (women with prior sPTB), as recommended by SMFM, then could also be utilized for other populations. Uncertainty of outcome of screening in actual practice compared to in controlled trials due to population differences, logistical differences in screening protocols, use of therapy beyond the scope of clinical trials or unintended adverse consequences of screening like more TVS or overuse of invasive procedures like cervical cerclage are cited as reasons against universal screening. However, these consequences are inherent in introduction of any proven test or therapy and should be a reason for formulation of strict guidelines and an effective quality assurance program, but not for not requiring the performance of a cost-effective beneficial screening test.

The definition of ‘sCL’ is open for debate. There is no cut-off CL when the risk for sPTB is increased; instead it is a

### Table 1 Levels of prevention

<table>
<thead>
<tr>
<th>Level of prevention</th>
<th>Stage of disease</th>
<th>Goal of therapy**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Pre-disease</td>
<td>Health promotion (reduce incidence of the disorder or number of new cases)</td>
</tr>
<tr>
<td>Secondary</td>
<td>Latent disease</td>
<td>Early identification and effective treatment (lower disease prevalence)</td>
</tr>
<tr>
<td>Tertiary</td>
<td>Symptomatic disease</td>
<td>Disease limitation for early symptomatic disease; Rehabilitation for late disease (reducing severity of impairment associated with disease)</td>
</tr>
</tbody>
</table>
Continuous variable. The risk of sPTB ≤ 32 weeks is 0.2% at CL of 60 mm at 20–24 weeks gestation, 0.8% at 30 mm, 1.1% at 25 mm, 1.5% at 20 mm, 4% at 15 mm, 15% at 10 mm, and 78% at 5 mm. Not only does the risk of sPTB increase as the CL decreases,10 there is a linear relationship between length of cervix and gestational age of prior sPTB.25 In addition, the risk of sPTB for a particular CL varies depending on the gestational age it was measured. For example, a CL of <25 mm at 20 weeks has a 40% chance of sPTB <35 weeks compared to 70% if detected at 16 weeks.26 Other important factors affecting the predictability of CL include number of fetuses, patient symptoms, and prior history of sPTB. Therefore, for clinical practice, the ‘cut-off’ CL at which to institute therapy will depend on the balance of detection rate and false positivity considered acceptable and most cost-effective. Current studies showing efficacy of therapies (vaginal progesterone or cervical cerclage) in women with ‘short cervix’ have all been in singleton gestations, asymptomatic women, and CL measured in midtrimester (Table 3) in women with and without prior sPTB.27–31 CL ‘cut-off’ used in

<table>
<thead>
<tr>
<th>Table 2 Clinically identifiable risk factors for spontaneous preterm birth</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sensitivity (%)</strong></td>
</tr>
<tr>
<td>Short cervix</td>
</tr>
<tr>
<td>(&lt;35 weeks)8,10,11</td>
</tr>
<tr>
<td>(&lt;32 weeks)8</td>
</tr>
<tr>
<td>Short cervix + vaginal bleeding</td>
</tr>
<tr>
<td>Prior sPTB</td>
</tr>
<tr>
<td>Fetal loss &lt; 16 weeks</td>
</tr>
<tr>
<td>Fetal loss 16–24 weeks</td>
</tr>
<tr>
<td>sPTB 24–32 weeks</td>
</tr>
<tr>
<td>Risk scoring system (&lt;37 weeks)57</td>
</tr>
<tr>
<td>Multiparous; Nulliparous66</td>
</tr>
<tr>
<td>Maternal factors (Age + Ob Hx) (&lt;32 weeks)52</td>
</tr>
<tr>
<td>Maternal factors + cervix length</td>
</tr>
<tr>
<td>(&lt;32 weeks)52</td>
</tr>
<tr>
<td>FFN+ (&lt;34 weeks)58</td>
</tr>
<tr>
<td>Vaginal bleeding (1st or 2nd trimester)</td>
</tr>
<tr>
<td>Bacterial vaginosis</td>
</tr>
<tr>
<td>Smoking</td>
</tr>
<tr>
<td>Illicit drug use/heavy alcohol use</td>
</tr>
</tbody>
</table>
| Maternal age < 20 years | | | 1.42%
| >35 years | | | 1.1 |
| Ethnicity – Black | | | 1.89 (1.1–3.27)66 |
| Prior cervical surgery | | | 1.66% |
| Body mass index < 19.8 | | | 1.0 % |
| >32.2 ± 2.2 kg/m² (<34 weeks) | | | 2.3 (1.37–3.92)66 |
| Clinical depression | | | 2.23 (1.19–4.18)75 |
| Socioeconomic status | | | <2-fold70 |
| Single marital status | | | 2.0 (1.19–3.44)66 |
| Long work hours/hard physical labor; stress | | | 1.4–1.846 |
| Interpregnancy interval < 6 months | | | <2-fold70 |
| Multple gestation | | | 2.275 |
| Polyhydramnios/oligohydramnios | | | (60)70 |
| Maternal medical and surgical disorders | | | 1.8 (1.03–3.15)77 |
| Uterine anomalies | | | 0.7–1.3466 |
| Intrauterine; vaginal or maternal systemic infections | | | 5.9 (4.3–8.1)74 |
| Periodontal disease | | | 2.83 (1.95–4.1)75 |
| No risk factors (>50% of all PTBs)29 | | | |

**Abbreviations:** FFN, fetal fibronectin; Ob Hx, obstetrical history; sPTB, spontaneous preterm births.
different studies has varied between $\leq 15–25$ mm. Based on current data, measurement of TVS CL is most appropriate between 19–$<$ 24 weeks and women with cervical length of 5–25 mm, with or without prior sPTB, would most benefit from vaginal progesterone, while women with prior sPTB and CL $\leq 15$ mm would most benefit from cervical cerclage.

### Vaginal progesterone

**Pharmacology, mode of action, pharmacokinetics**

Progesterone is a naturally occurring steroid hormone produced by the adrenals, gonads, nervous system, and placenta in pregnancy. It is a derivative of cholesterol. Cholesterol is converted into pregnenolone by enzyme cytochrome P450, and pregnenolone is converted to progesterone by 3β-hydroxy-steroid dehydrogenase/Δ5, Δ4 isomerase in the smooth endoplasmic reticulum (Figure 1).

Progesterone exerts its modulatory effects on target organs via intracellular receptor isoforms A (94 kDa) and B (116 kDa). The receptors are expressed by a single gene on chromosome 11q22-q23 but have separate translational start sites and promoters. Progesterone actions via membrane-based nongenomic receptors have also been illustrated. In therapeutics, progesterone is available in its natural form or synthetic form. Even though both forms are used for similar purposes, they are not chemically identical and their effect on target organs may not be similar.

The natural progesterone is chemically identical to the ovarian progesterone and synthesized from Mexican yams or soybean extracts or animal sources. Its micronization decreases particle size, increases surface area, and thus improves absorption. This results in exponential rise in bioavailability with decreased metabolic and vascular side effects.

The vaginal route further adds advantages to this form by rapid absorption and avoiding the first-pass hepatic metabolism, resulting in sustained plasma concentrations, and high bioavailability especially locally in the most desired target organ, the uterus. This has been termed as the ‘first uterine pass effect’ as progestational effects on the endometrium are seen despite low plasma levels suggesting direct transit of vaginal progesterone into the uterus. In addition to the above advantages, vaginal route possibly is the preferred mode of administration as the pain associated with oil-based intramuscular (IM) injections, bad taste associated with intranasal route, poor absorption and higher doses with oral route, conflicting evidence and variable effects with transdermal route, and inconvenience with the intravenous or rectal routes is avoided.

Vaginal progesterone is available in the form of gel, suppository, or pessary. Natural and micronized progesterone constitutes all the vaginal forms. Vaginal gel (Crinone/Prochieve; Watson Pharmaceuticals, Morristown, NJ) is the sustained release form with 90 mg progesterone in 1.125 g of gel with a 2% polycarbophil base. The capsule approved for oral use is used as vaginal suppository: 100 mg capsule in peanut oil (Utrogestan; Ferring Pharmaceuticals, West Drayton, UK and Prometrium; Abbott Laboratories, Abbott Park, IL). Compounded 100 or 200 mg suppositories in petroleum jelly base have also been used in USA. Recently a nonoil-based 100 mg progesterone tablet became available (Endometrin; Ferring Pharmaceuticals) for vaginal use. No pessary is available in the USA, but 200 mg and 400 mg progesterone pessary wrapped in wax is available in Europe (Cyclogest; Actavis UK, Devon, UK). All the above products are currently available and approved for other indications, but not for prevention of preterm labor.

Progesterone derives its name from ‘progestational steroid hormone’ due to its primary function of preparing and

### Table 3 Frequency of women with short cervix

<table>
<thead>
<tr>
<th>GA in weeks at screening</th>
<th>Cervical length (mm)</th>
<th>Percentiles</th>
<th>Mean/median CL (mm)</th>
<th>Funnel</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$\leq 15$</td>
<td>$\leq 20$</td>
<td>$\leq 25$</td>
<td>$\leq 30$</td>
</tr>
<tr>
<td>Fonseca$^{28}$</td>
<td>14–24</td>
<td>1.7%</td>
<td>8.3%</td>
<td></td>
</tr>
<tr>
<td>Heath$^{15}$</td>
<td>22–24</td>
<td>1.6%</td>
<td>3.4%</td>
<td>8.1%</td>
</tr>
<tr>
<td>Hassan$^{24}^{,74}$</td>
<td>14–24</td>
<td>0.6%</td>
<td>0.9%</td>
<td>1.7%</td>
</tr>
<tr>
<td>To$^{30,32}$</td>
<td>22–24</td>
<td>0.9%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iams$^{19}$</td>
<td>22–24</td>
<td>3.0%</td>
<td>7.8%</td>
<td>23.7%</td>
</tr>
<tr>
<td>Moroz$^{27}$</td>
<td>21–28</td>
<td>7.27%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hassan$^{29}$</td>
<td>19–24</td>
<td>7.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grobman$^{18}$</td>
<td>16–22</td>
<td>2.3%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: All were screened by transabdominal ultrasound, followed by TVS only if CL $< 30$ mm. In all other studies primary transvaginal screening was performed, suggesting greater detection with TVS; low-risk population with sPTB $\leq 32$ weeks of 0.6% (compared to 1.5% in the Heath cohort$^{30}$).

Abbreviations: CL, cervical length; sPTB, spontaneous preterm birth; TVS, transvaginal ultrasound.
Progesterone and progestins: neuroprotection and myelin repair.


Abbreviation: myelin repair.

The conversion of pregnenolone to progesterone by different isoforms of the 3β-hydroxysteroid dehydrogenase (3β-HSD) also takes place inside the mitochondria or within the cytoplasm. The transport of cholesterol across the mitochondrial membranes is a limiting step, and it involves the transport protein (TSPO). Ligands of TSPO can stimulate the passage of cholesterol into the mitochondria and, as a consequence, the synthesis of pregnenolone.

Notes: Progesterone regulates gene transcription by binding to intracellular receptors (PR), which interact as dimers with DNA-progesterone-response elements (PREs). In addition, PR can also directly interact with extranuclear signaling proteins of the Src/Ras/Erk pathway. At the level of the plasma membrane, progesterone binds to the recently identified membrane receptors of progesterone (mPR, comprising a, b, and g isoforms), progesterone receptor membrane component 1 (PGRMC1, the former protein 25Dx) and the s1 receptor. Major signal transduction pathways which have been shown to be activated by the mPRs are ERK and p38. The mPRs also inhibit adenylate cyclase (AC), and as a consequence the protein kinase A (PKA) pathway, and they stimulate Ca\(^{2+}\) release from internal stores. Likewise, PGRMC1 and s1 receptors increase intracellular Ca\(^{2+}\) release. Both receptors are also located on membranes inside the cytoplasm, but they may translocate from them to the plasma membrane. In addition, PGRMC1 has been shown to activate protein kinase G (PKG), and s1 receptors function as amplifiers of ion channels (eg, voltage-gated K- channels). Progesterone also activates \(\gamma\)-aminobutyric acid type A (GABA\(_A\)) receptors via its metabolite allopregnanolone.

Multiple mechanisms have been proposed to explain the role of progesterone in uterine quiescence and its deficiency (relative or absolute) resulting in parturition. In many animal species, systemic drop in progesterone levels heralds the onset of parturition. However, in humans, systemic progesterone levels remain high until after delivery of the placenta. Current evidence suggests that decrease in local progesterone responsiveness, termed ‘functional withdrawal’ heralds cervical remodeling. Progesterone effects gene transcription via activation of the progesterone receptor (PR) isoforms A and B. Progesterone-responsive genes are suppressed by PR-A, but activated by PR-B (Figure 1). The ratio of PR-A/PR-B determines progesterone action with an increase in PR-A expression initiating cervical ripening. Another mechanism proposed for the ‘functional’
Progesterone withdrawal is a decrease in PR coactivators, resulting in impaired progesterone–PR interaction, and thus reduced expression of progesterone-responsive genes. The differential expression of the PR is hypothesized to be mediated by PGs, inflammatory cytokines, and/or estrogen activation. Progesterone also exerts anti-inflammatory actions by inhibiting the transcription factor, nuclear factor-kB, which results in decreased cyclooxygenase-2 and PG synthase actions, and low PG levels. A second pathway to suppress PG production within the endometrium/decidua is to upregulate production of the unbound secretory component of immunoglobulin A (IgA) which directly inhibits phospholipase A2 and thus suppresses endometrial PG synthesis and release. In addition to the gene effects, progesterone can act via membrane-bound receptors and nongenomic pathways to suppress cytokine mediated inflammatory response. Progesterone decreases myometrial responsiveness by inhibiting estrogen receptor-α expression, and its byproducts competitively bind to oxytocin receptors and decrease oxytocin-induced contractility. Another hypothesis proposed for timing of labor is the maturation of the fetal hypothalamic–pituitary–adrenal axis resulting in cortisol secretion which regulates placental corticotrophin-releasing hormone (pCRH).77 CRH stimulates decidual PG secretion and increases myometrial responsiveness. Progesterone and cortisol have opposing actions in the fetoplacental unit and compete for regulation of pCRH gene expression. Exogenous progesterone supplementation may effectively restore some, but not all, of its actions to maintain uterine quiescence. This may explain why sPTB is prevented in some women using progesterone, but not universally. In others, the process of parturition may have progressed beyond the point of no return.

**Efficacy studies**

After the initial success of synthetic progesterone in prevention of recurrent sPTB in women with prior sPTB,48 investigation into the use of more convenient vaginal progesterone in this high-risk population was met with controversial findings.41,49 Looking at benefits of vaginal progesterone in other risk factors for sPTB only further heightened this controversy. The Turkish study in 150 high-risk women (with twins, uterine malformation or prior sPTB) showed lower sPTB and neonatal intensive care unit (NICU) admissions with use of 100 mg vaginal progesterone suppository,50 but the Danish study in 675 twin pregnancies showed no benefit from 200 mg vaginal suppository.51 However, controversial findings of these different studies suggested and helped identify a subgroup of particularly at-risk women for sPTB in which vaginal progesterone could be beneficial. The secondary analysis of the vaginal gel study in women with prior sPTB showed that using objective criteria such as ultrasonographically detected sCL, a stronger predictor of sPTB,10,52 was better able to identify women who could benefit from prophylactic treatment with vaginal progesterone.27 The investigators showed that daily use of 90 mg vaginal progesterone gel not only decreased risk of early sPTB ≤ 32 weeks in women with CL < 28 mm identified between 18.0 and 22.9 weeks of gestation, but also improved neonatal outcomes, the ultimate goal of therapy. The sPTB rate with vaginal gel progesterone compared to placebo (Replens®; Columbia Laboratories, Inc, Livingston, NJ) was 0 vs 29.6%; P = 0.01; lower NICU admissions (15.8 vs 51.9%, P = 0.01); shorter NICU stay (1.1 vs 16.5 days; P = 0.01), and a trend towards lower occurrence of respiratory distress syndrome (RDS) (5.3% vs 29.6%; P = 0.06). At the same time, the Fetal Medicine Foundation second trimester screening group from London, UK had reported 44% lower sPTB < 34 weeks with once-daily 200 mg progesterone suppositories (19.2% vs 34.4%; P = 0.007) in women with 20–25 week CL ≤ 15 mm.28 However, they noted a nonsignificant reduction in composite adverse neonatal outcomes (8.1% vs 13.8%; P = 0.17). Subsequently the largest-to-date prospective, randomized, placebo-controlled, double-blind, parallel-group study was conducted at 44 centers in 10 countries using progesterone vaginal gel in women with 19–<24 week CL of 10–20 mm.29 In the 458 women enrolled, the gel decreased sPTB < 33 weeks by 45% in comparison to placebo users (8.9% vs 16.1%; P = 0.02). There was also a 38% reduction in sPTB < 35 (14.5% vs 23.3%; P = 0.02) and a 50% reduction <28 weeks (5.1% vs 10.3%; P = 0.04). Improvement in neonatal outcome was also demonstrated with lower incidence of RDS (3% vs 7.6%; P = 0.03); lower rate of any morbidity or mortality (7.7% vs 13.5%, P = 0.04); and reduction in neonates with birth weight < 1500 g (6.4% vs 13.6%; P = 0.01). Romero and colleagues then conducted an individual patient data meta-analysis of randomized controlled trials in asymptomatic women with midtrimester CL ≤ 25 mm, as the resultant larger sample size would provide greater statistical power for subgroup analyses, improve standardization and consistency across data sets, and allow time-to-event analyses.30 Analysis of 775 women (723 singleton and 52 twin pregnancies) confirmed reduction in risk of sPTB < 33 weeks in both women with singleton gestation without prior sPTB (relative risk [RR] = 0.60; 95% confidence interval [CI]: 0.39–0.92)
as well as women with ≥1 prior sPTB (RR = 0.54; 95% CI: 0.30–0.98) with improved composite neonatal outcomes in both groups. In singletons, neonatal outcomes significantly improved were RDS (RR = 0.47; 95% CI: 0.27–0.81); composite neonatal morbidity and mortality (RR = 0.59; 95% CI: 0.38–0.91); apgar score < 7 at 5 minutes (RR = 0.48; 95% CI: 0.24–0.95); NICU admissions (RR = 0.67; 95% CI: 0.50–0.91); and birth weight < 1500 g (RR = 0.52; 95% CI: 0.34–0.81). The meta-analysis recommended a future, properly designed study in twin pregnancies with short cervix as the analysis showed nonsignificant reductions in early sPTB < 33 weeks (RR = 0.70; 95% CI: 0.34–1.44); and <28 weeks (RR = 0.44, 95% CI: 0.11–1.85) but significant reduction in composite neonatal morbidity and mortality (RR = 0.52; 95% CI: 0.29–0.93).

**Comparative studies**

Currently, there are no studies comparing any of the formulations of progesterone to each other for prevention of sPTB. However, for luteal phase support in women undergoing assisted reproductive technologies, vaginal progesterone (oil-in-capsule or the gel) was comparable to the IM form on the clinical end-points (clinical pregnancy and ongoing pregnancies). Pharmacokinetic comparisons have shown higher endometrial tissue levels despite lower serum levels with vaginal (1.05 ± 0.67 ng/mg protein and 4.82 ± 2.25 ng/mL, respectively) compared to IM (0.43 ± 0.19 ng/mg protein and 29.42 ± 14.14 ng/mL, respectively) preparations.

**Vaginal gel progesterone**

**Safety and tolerability**

The synthetic progestogenes administered parenterally result in undesirable side effects like alteration in lipid levels, glucose metabolism, a hypercoagulant state, vasomotility, edema, central nervous system effects like sedation, fatigue, dizziness and dysphoria, gastrointestinal effects like abdominal cramps, back pain, nausea, and constipation; reproductive system effects like vaginal bleeding and breast tenderness. These side effects are decreased with the micronized form and systemic effects almost eliminated with the vaginal form. The most common side effects reported with the vaginal form include vaginal discharge, vaginal pruritus, drowsiness, nausea, and ‘feeling of coolness’ in the vagina.

The gel formulation contains 90 mg micronized progesterone mixed in a small volume of nonimmunogenic polycarbophil gel, which is an oil-in-water emulsion. The polycarbophil base attaches to the vaginal epithelial cells until they turn over every 3–5 days. The progesterone is partially soluble in both oil and water phases, with the aqueous form being absorbed by facilitated diffusion across the vaginal wall. The progesterone stored in the oil reservoir replaces the depleted aqueous form, resulting in controlled release of the drug. So the gel form does not result in leakage, unlike the suppositories which can be messy as the oil base liquefies at body temperature. The resulting leakage causes vaginal irritation and yeast infections at ten times greater frequency with suppositories compared to the gel formulation. However, the gel can result in vaginal build-up, cloddy discharge, and vaginal irritation in up to 2%–4% of patients in the 2nd and 3rd trimesters and 7% in the 1st trimester. The increased incidence in the 1st trimester is most likely due to more frequent administration. These side effects are due to the vehicle rather than the drug itself.

Safety of progesterone is well established in the 1st trimester and exemplified by its popular use for luteal phase support in both natural and assisted pregnancies. Safety in the 2nd and 3rd trimesters has only recently been established in prospectively randomized, double-blind, placebo-controlled trials. In a meta-analysis, no difference was noted between progesterone and placebo groups with respect to congenital anomalies (1.5 vs 1.7%; 95% CI: 0.55–1.44); any maternal adverse event (13.8 vs 13.4%; 95% CI: 0.79–1.38); vaginal discharge (22.9 vs 23.5%; 95% CI: 0.87–1.15); and vaginal pruritus (5.1 vs 4.7%; 95% CI: 0.74–1.57). Rate of therapy discontinuation due to gel side effects was 1.6% in one study (one patient stopped due to vaginal discharge and other two due to nausea) and overall with all vaginal formulations was 2.6% in both drug and placebo groups. Follow-up of neonates was reported in two trials, one using the suppository and the other using the gel. Rode and colleagues reported neurodevelopmental disability using the Ages and Stages Questionnaire (ASQ) scores in neonates exposed to progesterone suppositories in the PREDICT trial at 6 (79.2%) and 18 months (74.8%). The mean ASQ scores (193 ± 42.6 vs 194 ± 40.6; P = 0.89) or the proportions below 115 at 18 months were similar (3.8% vs 3.7% in the progesterone and placebo groups, respectively). Infants exposed to the vaginal gel trial were evaluated at 6 (69.9%), 12 (61.1%), and 24 months (46%) for biometric growth, developmental debilities by Denver II screening test (10.3% vs 10.4%; 95% CI: 0.62–1.55), chronic morbid conditions (5.6% vs 5.4% 95% CI: 0.55–1.99) and congenital abnormalities (3.4% vs 3.8%; 95% CI: 0.4–2.01). Again, no differences were noted between progesterone and placebo groups in neonatal parameters up to 24 months.
**Patient-focused perspectives patient satisfaction/acceptability, adherence**

Overall vaginal progesterone is safe for the mother and fetus with minimal side-effects when compared to placebo. The adverse effects are similar with all vaginal forms of progesterone.\(^{54}\) Comparing vaginal gel to oil-in-capsules, patients find the gel more convenient and easy to use as there is less vaginal discharge and fewer application difficulties.\(^{61,62}\) Despite equivalent efficacy of different forms of natural progesterone, the gel provides superior acceptability and tolerability due to less leakage and once daily application with a tampon-like familiar insertion.\(^{61}\) In the reported trials, over 98% patients accepted a complete course of vaginal gel therapy with high compliance rates of 93%–96%.\(^{29,49}\) Women express greater satisfaction with the convenience of administration of vaginal gel progesterone compared to the discomfort with IM progesterone.\(^{63}\)

**Conclusion: place in therapy**

In summary, there is ample Level 1 evidence supporting use of vaginal progesterone in women with midtrimester short cervix to decrease sPTB. Adding to this benefit is the fact that it has no significant adverse effects for mother or the neonate. Critics argue that with low frequency of sCL (Table 3), low sensitivity of sCL to predict preterm delivery, and only ~40% reduction of sPTB will result in many women undergoing the treatment unnecessarily. However, proponents would argue that the data suggests that only 11 need to be treated to prevent one sPTB.\(^{41}\) This one prevented sPTB will result in insurmountable benefits not only to that neonate, but also to that family, and the society not only monetarily but also emotionally and intellectually and lighten the burden of chronic diseases. Even if critics argue regarding the degree of benefit, the risk–benefit ratio balance tips towards vaginal progesterone use in women with sCL especially as there are no significant side effects. Therefore I recommend universal CL screening of all women with singleton gestation at midtrimester, and offering prophylactic treatment with vaginal progesterone in those with sCL. I believe this will become the standard of care.

**Disclosure**

The author was an investigator in the ‘PREGNANT’ trial, and was also a paid consultant as part of the Watson Pharmaceutical Team presenting to FDA in 2011 for vaginal progesterone gel.

**References**


